| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_688fc56583d3e643b01510e16a890508
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_925a1691eb31c0b17afda79be826ba1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a36625f4b69524ae319d0707208bdf4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_11ba1020e0cbd84a7da13c3436e61b84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae2c42ae4ccdb2fb52fdd900b4a92bd9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16C20-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A90-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-743
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B15-30 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G06F19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B15-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
| filingDate |
2003-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_521da264ac89d82c233f8300428205bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8eb853a4367fd17bcea4ff6ce4bb1965
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31bad0f1fb28b5c9cde35d23961f99ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c25ba0e1b3318708a25ef30ac15be3c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a768e6d9f7bece109de7db60ae13c605 |
| publicationDate |
2007-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2007087352-A9 |
| titleOfInvention |
Inhibitors for androgen antagonist refractory prostate cancer |
| abstract |
The present invention relates to methods and antagonist compounds for modulating androgen receptor activity. The invention includes a method for identifying molecules that bind to a coactivator binding site of a receptor in the androgen receptor family. Also included is a cocrystal of an androgen receptor ligand binding domain complexed with a ligand and a coactivator. The invention further includes a method for inhibiting androgen receptor activity in a mammal, thereby facilitating treatment of diseases such as prostate cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023064874-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11290682-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10950271-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11514947-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10438631-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11651797-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11443772-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10566026-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10586570-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10991395-B1 |
| priorityDate |
2003-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |